• / Free eNewsletters & Magazine
  • / My Account
Home>Global Lysosomal Storage Diseases Market - Analysis, Technologies & Forecasts to 2021 - Research and Markets

Global Lysosomal Storage Diseases Market - Analysis, Technologies & Forecasts to 2021 - Research and Markets

Global Lysosomal Storage Diseases Market - Analysis, Technologies & Forecasts to 2021 - Research and Markets

09/29/2017

Global Lysosomal Storage Diseases Market - Analysis, Technologies & Forecasts to 2021 - Research and Markets

The "Global Lysosomal Storage Diseases Market 2017-2021" report has been added to Research and Markets' offering.

The global lysosomal storage diseases market is forecast to grow at a CAGR of 7.43% during the period 2017-2021.

The report, Global Lysosomal Storage Diseases Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is regulatory assistance in emerging nations. The global LSDs market is expected to post a rapid CAGR, especially in emerging markets because of increasing legislative changes in these countries. These changes are aimed at promoting research and development for rare diseases.

According to the report, one driver in the market is unmet medical needs. The need for efficacious therapeutics that can either slow or reverse the progression of disease is on the rise in the market. The therapeutic options available to treat LSDs is very limited, especially in particular disease subsets such as Gaucher disease type II. The inability of the available treatments to improve neurological symptoms associated with LSDs because of the limited penetration of blood brain barrier (BBB) by ERTs also represent a high unmet need for this disease. For instance, there is a lack of safe treatment options for early stages of Pompe disease.

Key vendors

  • Actelion Pharmaceuticals
  • BioMarin
  • Genzyme
  • Shire

Other prominent vendors

©2017 Morningstar Advisor. All right reserved.